Cessatech

17.95 DKK

+6.85 %

Less than 1K followers

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+6.85 %

+5.59 %

-20.75 %

+12.47 %

+41.34 %

+32.18 %

+1,004.62 %

-13.45 %

+66.44 %

Cessatech is a pivotal-stage paediatric biotech company developing first-in-class specialty hospital medicines for children, focused on high-impact unmet needs in acute and emergency care. The company focuses on specialty products designed for use in clinical settings and advances its programs through a partnership-based development model. Founded in 2020, Cessatech is headquartered in Denmark and led by a team with experience across drug development and commercialization.

Market cap

333.45M DKK

Turnover

180.77K DKK

Revenue

5.72M

EBIT %

-261.75 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

28/5

2026

Interim report Q1'26

28/8

2026

Interim report Q2'26

26/11

2026

Interim report Q3'26

All

Press releases

ShowingAll content types

Regulatory press release3/30/2026, 9:45 AM

Minutes from the Annual General Meeting in Cessatech A/S

Regulatory press release3/13/2026, 7:30 AM

Cessatech convenes its Annual General Meeting

Regulatory press release2/27/2026, 7:30 AM

Cessatech A/S Announces Financial Results for the Full Year 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release2/2/2026, 7:00 AM

Cessatech: Welcome to the first quarter of 2026

Regulatory press release11/13/2025, 7:30 AM

Cessatech: Third Quarter Report Q3-2025

Regulatory press release10/31/2025, 12:00 PM

Cessatech: CT001 soon available for US hospitals in collaboration with STAQ Pharma, for acute pain management in children

Regulatory press release8/21/2025, 6:30 AM

Cessatech: Second Quarter Report Q2-2025

Regulatory press release8/14/2025, 4:00 PM

Cessatech: The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children

Press release6/27/2025, 11:31 AM

Cessatech Q&A - June company presentation

Regulatory press release6/19/2025, 11:30 AM

Cessatech strengthens Executive Management with the promotion of Martin Juhl

Regulatory press release6/11/2025, 12:15 PM

Cessatech announce completion of the directed issue of shares

Regulatory press release5/28/2025, 8:30 PM

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Regulatory press release5/28/2025, 3:30 PM

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Regulatory press release5/28/2025, 3:15 PM

Cessatech announces positive top-line results from its final CT001 Study 0202

Regulatory press release5/15/2025, 6:30 AM

Cessatech: First Quarter Report Q1-2025

Regulatory press release4/30/2025, 1:45 PM

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Regulatory press release3/28/2025, 10:30 AM

Minutes from the Annual General Meeting in Cessatech A/S

Regulatory press release3/12/2025, 7:30 AM

Cessatech: Annual General Meeting - 28 March 2025

Regulatory press release2/28/2025, 7:30 AM

Cessatech A/S publishes Annual Report for the fiscal year 2024

Regulatory press release2/4/2025, 10:30 AM

Cessatech receives positive Notified Body opinion under MDR for CT001

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.